← Back
NeuroTrials.ai
Neurology Clinical Trial Database

ENCHANTED (Swelling Analysis)

Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results

Year of Publication: 2025

Authors: Guobin Zhang, Chen Chen, Xinwen Ren, ..., for the ENCHANTED Investigators

Journal: Stroke

Citation: Stroke. 2025;56:1388–1395. DOI: 10.1161/STROKEAHA.124.049938

Link: https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049938


Clinical Question

Does early intensive blood pressure lowering reduce cerebral swelling in patients with acute ischemic stroke treated with thrombolysis?

Bottom Line

Early intensive BP lowering to 130–140 mm Hg did not significantly reduce cerebral swelling compared to guideline-recommended BP control (<180 mm Hg) in thrombolyzed patients with AIS.

Major Points

  • Secondary analysis of the ENCHANTED trial focused on cerebral swelling after IV alteplase in AIS.
  • 1477/2196 patients had any follow-up brain imaging (intensive n=725, guideline n=752); swelling score was assessed in 1465 (intensive n=719, guideline n=746).
  • No significant difference in cerebral swelling: 22.12% (guideline) vs 22.39% (intensive) (aOR 1.05, 95% CI 0.81–1.36; p=0.71).
  • Ordinal shift in swelling scores and midline shift measurements showed no significant differences.
  • BP difference between groups was modest (mean Δ 6.6 mm Hg).
  • Reassuring safety data support intensive BP lowering in thrombolyzed AIS but no benefit on brain swelling.

Design

Study Type: Randomized, open-label, blinded endpoint (PROBE) trial

Randomization: 1

Blinding: Blinded imaging endpoint assessment

Enrollment Period: March 2012 – April 2018

Follow-up Duration: Primary follow-up imaging within 24 hours post-randomization; sensitivity analysis restricted to scans at 24–96 hours; median time from symptom onset to selected follow-up imaging 27.4h (IQR 24.6–31.9)

Centers: 110

Countries: 15 countries (including Australia, China, Korea, Brazil, Chile, UK)

Sample Size: 2196

Analysis: Logistic and ordinal regression, intention-to-treat, adjusted for clinical covariates


Inclusion Criteria

  • Acute ischemic stroke eligible for IV thrombolysis
  • Systolic BP ≥150 mm Hg at baseline
  • Treatment within 6 hours of symptom onset

Exclusion Criteria

  • Contraindication to thrombolysis
  • Severe comorbid illness or anticipated poor prognosis
  • Unavailable follow-up brain imaging

Baseline Characteristics

Mean Age: 67.7 (±12.1)

Female %: 39.6%

SBP: 165.9 (±9.5)

DBP: 91.3 (±11.7)

Hypertension: 73.3%

Diabetes: 20.9%

Hyperlipidemia: 14.2%

Smoker: 21.9%


Arms

FieldIntensive BP loweringControl
InterventionIV BP-lowering agents to target systolic 130–140 mm Hg within 1 hour, maintained for 72hStandard BP management to systolic <180 mm Hg
Duration72 hours72 hours

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Any brain swelling (score 1–6) on follow-up imagingPrimary22.12%22.39%1.05 (adjusted)0.71
Swelling score 2–6Secondary10.46%10.01%aOR 1.00 (0.70–1.42)1.00
Swelling score 3–6Secondary2.55% (19/746)3.26% (26/719)aOR 1.62 (0.85–3.08)0.15
Swelling score 4–6Secondary2.28% (17/746)2.50% (18/719)aOR 1.17 (0.57–2.43)0.67
Change in swelling score (worsened)Secondary28.61%27.98%aOR 1.12 (0.78–1.59)0.55
Midline shift (mm)Secondary8.85 mm6.47 mmadjusted MD −1.78 (−5.73 to 2.17)0.17
Parenchymal hemorrhage (PH1/2)Adverse8%6%0.12

Subgroup Analysis

No heterogeneity across prespecified subgroups (age, sex, SBP, time to randomization, scan type, infarct size, alteplase dose, premorbid status, etc.)


Criticisms

  • Modest BP difference between groups (6.6 mm Hg) may have limited detectable effect
  • Swelling scale may not capture true edema volume
  • Only 67% of trial population included due to imaging availability
  • Follow-up imaging often closer to 24h than 72h—may miss peak swelling
  • Secondary analysis not powered for edema outcome

Funding

National Health and Medical Research Council of Australia; Stroke Association (United Kingdom); National Council for Scientific and Technological Development (Brazil; grants 467322/2014–7, 402388/2013–5); Ministry for Health, Welfare and Family Affairs (Republic of Korea; HI14C1985)

Based on: ENCHANTED (Swelling Analysis) (Stroke, 2025)

Authors: Guobin Zhang, Chen Chen, Xinwen Ren, ..., for the ENCHANTED Investigators

Citation: Stroke. 2025;56:1388–1395. DOI: 10.1161/STROKEAHA.124.049938

Content summarized and formatted by NeuroTrials.ai.